BioMarin sees Amicus acquisition accretive to EPS in first year post close

The transaction is expected to: Accelerate Revenue Growth. The acquisition is expected to increase BioMarin’s (BMRN) long-term CAGR through 2030 and beyond. Both Galafold and Pombiliti + Opfolda have high-growth potential and generated combined net product revenues over the past four quarters totaling $599M. Based on the Galafold litigation settlements announced today, U.S. exclusivity for Galafold is expected through January 2037. Diversify the Commercial Portfolio. The acquisition will add two therapies to BioMarin’s Enzyme Therapies Business Unit and provide expansion opportunities for Galafold and Pombiliti + Opfolda across BioMarin’s global footprint. Create Substantial Shareholder Value. The acquisition will add revenue immediately after the transaction closes. It is expected to be accretive to Non-GAAP Diluted EPS in the first 12 months after close and substantially accretive beginning in 2027. With strong cash flow generation and a commitment to deleveraging, BioMarin is targeting gross leverage less than2.5x within two years after close. Support BioMarin’s Strategic Priorities. This acquisition demonstrates execution of BioMarin’s capital allocation strategy to leverage the company’s financial strength to diversify its pipeline and add innovative new therapies for patients.